{
  "nctId": "NCT02336815",
  "briefTitle": "Selinexor Treatment of Refractory Myeloma",
  "officialTitle": "A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab",
  "protocolDocument": {
    "nctId": "NCT02336815",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2017-12-13",
    "uploadDate": "2020-07-24T09:48",
    "size": 1449251,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02336815/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NON_RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 202,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2015-05-26",
    "completionDate": "2019-07-26",
    "primaryCompletionDate": "2019-07-26",
    "firstSubmitDate": "2015-01-08",
    "firstPostDate": "2015-01-13"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\nMeasurable MM based on modified IMWG guidelines. Defined by at least one of the following:\n\n1. Serum M-protein ≥ 0.5 g/dL by serum electrophoresis (SPEP) or for IgA myeloma, by quantitative IgA\n2. Urinary M-protein excretion ≥ 200 mg/24 hours\n3. Free Light Chain (FLC) ≥ 100 mg/L, provided that the FLC ratio is abnormal\n4. If serum protein electrophoresis is felt to be unreliable for routine M-protein measurement, then quantitative Ig levels by nephelometry or turbidimetry are acceptable\n\n   * Must have previously received ≥ 3 anti-MM regimens including: an alkylating agent, lenalidomide, pomalidomide, bortezomib, carfilzomib, daratumumab, and a glucocorticoid. There is no upper limit on the number of prior therapies provided that all other inclusion/exclusion criteria are met.\n   * MM refractory to previous treatment with one or more glucocorticoids, parenteral PI (i.e., bortezomib and/or carfilzomib), IMiD (i.e., lenalidomide and/or pomalidomide), and the anti-CD38 mAb, daratumumab. Refractory is defined as ≤ 25% response to therapy, or progression during therapy or progression within 60 days after completion of therapy.\n\nExclusion Criteria:\n\n* Active smoldering MM.\n* Active plasma cell leukemia.\n* Documented systemic amyloid light chain amyloidosis.\n* Active CNS MM.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Part 2: Percentage of Participants With Overall Response Rate (ORR) Per International MyelomaWorking Group (IMWG) as Assessed by an Independent Review Committee (IRC)",
        "description": "IRC assessed ORR per 2016 IMWG criteria: Percentage of participants who experienced Partial response (PR): greater than or equal to (\\>=) 50 percent (%) reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \\>= 90% or to lesser than (\\<) 200 mg per 24 hours; Very good partial response (VGPR): Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \\< 100 mg per 24 hours; Complete response (CR): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and lesser than or equal to (\\<=) 5% plasma cells in bone marrow; or stringent complete response (sCR): CR as defined+Normal free light chain (FLC) ratio+Absence of clonal cells in bone marrow biopsy by immunohistochemistry).",
        "timeFrame": "Baseline until disease progression/discontinuation from the study, or death, whichever occurred first (maximum duration of 17 months)"
      }
    ],
    "secondary": [
      {
        "measure": "Part 1: Duration of Response (DoR) Per IMWG as Assessed by IRC",
        "description": "IRC assessed DoR per 2016 IMWG criteria: time (in months) from the first documentation of objective response (confirmed CR or PR) to the date of first documentation of progressive disease (PD) or death due to any cause. Partial response (PR): \\>= 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \\>= 90% or to \\< 200 mg per 24 hours; Complete response (CR): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\<= 5% plasma cells in bone marrow; Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \\>= 0.5 gram per deciliter (g/dL); Serum M-protein increase \\>= 1 g/dL if the lowest M-component was \\>=5 g/dL; Urine M-protein (absolute increase must be \\>= 200 mg per 24 hours). Analysis was performed using Kaplan-Meier method.",
        "timeFrame": "First response subsequently confirmed to disease progression/discontinuation from the study, or death, whichever occurred first (maximum duration of 13 months)"
      },
      {
        "measure": "Part 2: Duration of Response (DoR) Per IMWG as Assessed by an IRC",
        "description": "IRC assessed DoR per 2016 IMWG criteria: time (in months) from the first documentation of objective response (confirmed CR or PR) to the date of first documentation of progressive disease (PD) or death due to any cause. Partial response (PR): \\>= 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \\>= 90% or to \\< 200 mg per 24 hours; Complete response (CR): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\<= 5% plasma cells in bone marrow; Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \\>= 0.5 g/dL; Serum M-protein increase \\>= 1 g/dL if the lowest M-component was \\>= 5 g/dL; Urine M-protein (absolute increase must be \\>= 200 mg per 24 hours). Analysis was performed using Kaplan-Meier method.",
        "timeFrame": "First response subsequently confirmed to disease progression/discontinuation from the study, or death, whichever occurred first (maximum duration of 17 months)"
      },
      {
        "measure": "Part 1: Percentage of Participants With Clinical Benefit Rate (CBR) ) Per IMWG as Assessed by IRC",
        "description": "IRC assessed CBR per 2016 IMWG criteria: Percentage of participants with a confirmed minimal response (MR) or better (PR, VGPR, CR or sCR) before confirmed disease progression or initiating new MM treatment. Minimal response (MR): \\>= 25% but \\< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%. Partial response (PR): \\>= 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \\>= 90% or to \\< 200 mg per 24 hours; Very good partial response (VGPR): Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \\< 100 mg per 24 hours; Complete response (CR): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\<= 5% plasma cells in bone marrow; or stringent complete response (sCR): CR as defined+Normal free light chain (FLC) ratio+Absence of clonal cells by immunohistochemistry).",
        "timeFrame": "Baseline up to a maximum of 13 months"
      },
      {
        "measure": "Part 2: Percentage of Participants With Clinical Benefit Rate (CBR) Per IMWG as Assessed by IRC",
        "description": "IRC assessed CBR per 2016 IMWG criteria: Percentage of participants with a confirmed minimal response (MR) or better (PR, VGPR, CR or sCR) before confirmed disease progression or initiating new MM treatment. Minimal response (MR): \\>= 25% but \\< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%. Partial response (PR): \\>= 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \\>= 90% or to \\< 200 mg per 24 hours; Very good partial response (VGPR): Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \\< 100 mg per 24 hours; Complete response (CR): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\<= 5% plasma cells in bone marrow; or stringent complete response (sCR): CR as defined+Normal free light chain (FLC) ratio+Absence of clonal cells by immunohistochemistry).",
        "timeFrame": "Baseline up to a maximum of 17 months"
      },
      {
        "measure": "Part 1: Duration of Clinical Benefit Per IMWG as Assessed by IRC",
        "description": "IRC assessed duration of clinical benefit per 2016 IMWG criteria: Duration from first response (at least MR) to time of IRC-determined PD or death due to disease progression, whichever occurs first. Minimal response (MR): \\>= 25% but \\< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%. Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \\>= 0.5 g/dL; Serum M-protein increase \\>= 1 g/dL if the lowest M-component was \\>=5 g/dL; Urinary M-protein (absolute increase must be \\>= 200 mg per 24 hours). Analysis was performed using Kaplan-Meier method.",
        "timeFrame": "First response subsequently confirmed to disease progression, or death, whichever occurred first (maximum duration of 13 months)"
      },
      {
        "measure": "Part 2: Duration of Clinical Benefit Per IMWG as Assessed by IRC",
        "description": "IRC assessed duration of clinical benefit per 2016 IMWG criteria: Duration from first response (at least MR) to time of IRC-determined PD or death due to disease progression, whichever occurs first. Minimal response (MR): \\>= 25% but \\< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%. Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \\>= 0.5 g/dL; Serum M-protein increase \\>= 1 g/dL if the lowest M-component was \\>=5 g/dL; Urinary M-protein (absolute increase must be \\>= 200 mg per 24 hours). Analysis was performed using Kaplan-Meier method.",
        "timeFrame": "First response subsequently confirmed to disease progression, or death, whichever occurred first (maximum duration of 17 months)"
      },
      {
        "measure": "Part 2: Disease Control Rate (DCR)",
        "description": "DCR was defined as the percentage of participants who achieved stable disease (SD) or better (MR, PR, VGPR, CR, sCR) for a minimum of 12 weeks. Stable disease (SD): Not recommended for use as an indicator of response; stability of disease was best described by providing the time to progression (TTP) estimates. MR: \\>= 25% but \\< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%. PR: \\>=50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \\>= 90% or to \\< 200 mg per 24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \\< 100 mg per 24 hours; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\<= 5% plasma cells in bone marrow; or sCR: CR as defined+Normal FLC ratio+Absence of clonal cells by immunohistochemistry).",
        "timeFrame": "Every 12 weeks until progressive disease or death due to any cause, up to 17 months"
      },
      {
        "measure": "Part 1: Progression Free Survival (PFS) Per IMWG as Assessed by IRC",
        "description": "IRC assessed PFS per 2016 IMWG criteria: Duration from start of study treatment until IRC-determined progressive disease (PD) or death from any cause, whichever occurred first. Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \\>= 0.5 g/dL; Serum M-protein increase \\>=1 g/dL if the lowest M-component was \\>= 5 g/dL; Urinary M-protein (absolute increase must be \\>= 200 mg/24 hours). Analysis was performed using Kaplan-Meier method.",
        "timeFrame": "From start of study treatment to progression of disease or discontinuation from the study or death, whichever occurred first (maximum duration of 13 months)"
      },
      {
        "measure": "Part 2: Progression Free Survival (PFS) Per IMWG as Assessed by IRC",
        "description": "IRC assessed PFS per 2016 IMWG criteria: Duration from start of study treatment until IRC-determined progressive disease (PD) or death from any cause, whichever occurred first. Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \\>= 0.5 g/dL; Serum M-protein increase \\>=1 g/dL if the lowest M-component was \\>= 5 g/dL; Urinary M-protein (absolute increase must be \\>= 200 mg/24 hours). Analysis was performed using Kaplan-Meier method.",
        "timeFrame": "From start of study treatment to progression of disease or discontinuation from the study or death, whichever occurred first (maximum duration of 17 months)"
      },
      {
        "measure": "Part 1: Time to Progression (TTP) Per IMWG as Assessed by IRC",
        "description": "IRC assessed TTP per 2016 IMWG criteria: Duration from start of study treatment until PD or death due to PD (per IRC), whichever occurred first. Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \\>= 0.5 g/dL; Serum M-protein increase \\>=1 g/dL if the lowest M-component was \\>= 5 g/dL; Urinary M-protein (absolute increase must be \\>= 200 mg/24 hours). Analysis was performed using Kaplan-Meier method.",
        "timeFrame": "From start of study treatment to progression of disease or death, whichever occurred first (maximum duration of 13 months)"
      },
      {
        "measure": "Part 2: Time to Progression (TTP) Per IMWG as Assessed by IRC",
        "description": "IRC assessed TTP per 2016 IMWG criteria: Duration from start of study treatment until PD or death due to PD (per IRC), whichever occurred first. Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \\>= 0.5 g/dL; Serum M-protein increase \\>=1 g/dL if the lowest M-component was \\>= 5 g/dL; Urinary M-protein (absolute increase must be \\>= 200 mg/24 hours). Analysis was performed using Kaplan-Meier method.",
        "timeFrame": "From start of study treatment to progression of disease or death, whichever occurred first (maximum duration of 17 months)"
      },
      {
        "measure": "Part 1: Time to Next Treatment (TTNT)",
        "description": "TTNT was defined as the duration from start of study treatment to start of next anti-MM treatment or death due to disease progression, whichever occurred first. Analysis was performed using Kaplan-Meier method.",
        "timeFrame": "From start of study treatment to start of next anti-MM treatment or death due to disease progression, whichever occurs first (maximum duration of 13 months)"
      },
      {
        "measure": "Part 2: Time to Next Treatment (TTNT)",
        "description": "TTNT was defined as the duration from start of study treatment to start of next anti-MM treatment or death due to disease progression, whichever occurred first. Analysis was performed using Kaplan-Meier method.",
        "timeFrame": "From start of study treatment to start of next anti-MM treatment or death due to disease progression, whichever occurs first (maximum duration of 17 months)"
      },
      {
        "measure": "Part 1: Overall Survival (OS)",
        "description": "OS was defined as the duration (in months) from start of study treatment to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier. Analysis was performed using Kaplan-Meier method.",
        "timeFrame": "From start of study treatment to death (maximum duration of 13 months)"
      },
      {
        "measure": "Part 2: Overall Survival (OS)",
        "description": "OS was defined as the duration (in months) from start of study treatment to death from any cause. Participants last known to be alive were censored at the date of discontinuation from the study, or database cut date, whichever was earlier. Analysis was performed using Kaplan-Meier method.",
        "timeFrame": "From start of study treatment to death (maximum duration of 17 months)"
      },
      {
        "measure": "Part 2: Change From Baseline in Health-related Quality of Life (HRQL) Score Based on Functional Assessment of Cancer Therapy - Multiple Myeloma (FACT-MM) Questionnaire",
        "description": "FACT-MM combines the general version of the FACT (FACT-G) with a MM-specific sub-scale (14 items). The sub-scales for the FACT-G are Physical Well-Being (7 items), Social/Family Well-Being (7 items), Emotional Well-Being (6 items), and Functional Well-Being (7 items). The trial outcomes index (TOI); total of 41 items) is the primary measurement of interest, comprised of the Physical and Functional sub-scales plus the MM-specific sub-scale. Each item is rated on a 5-point Likert scale, ranging from 0 (\"Not at all\") to 4 (\"Very much\"), therefore the TOI has a score ranging from 0 to 120. Higher scores indicated improvement in well being.",
        "timeFrame": "Baseline, Day 1 of Cycle 2 to Cycle 20 (up to a maximum of 17 months)"
      },
      {
        "measure": "Number of Participants With Treatment-Emergent Adverse Events (TEAE) of Grade 3/4, Graded Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.03",
        "description": "An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per NCI-CTCAE version 4.03, Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. Treatment-emergent events are events between first dose of study drug and up to last dose of study treatment + 30 days (inclusive) that were absent before treatment or that worsened relative to pre-treatment state.",
        "timeFrame": "Baseline to 30 days after last dose of study treatment (maximum duration of 18 months)"
      },
      {
        "measure": "Number of Participants With Treatment-Emergent Treatment-Related Adverse Events (TEAEs) of Grade 3/4, Graded Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.03",
        "description": "An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per NCI-CTCAE version 4.03, Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. A treatment related AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event had a causal relationship with the treatment or usage.",
        "timeFrame": "Baseline to 30 days after last dose of study treatment (maximum duration of 18 months)"
      },
      {
        "measure": "Apparent Clearance (CL/F) of Selinexor in Plasma",
        "description": "CL/F of selinexor in plasma was reported.",
        "timeFrame": "Cycle 1: Day 1: Pre-dose, 1, 2 and 4 hours post-dose; Day 8 and 15: Pre-dose and 1 hour post-dose; Cycle 2: Day 1: Predose, 1, 2 and 4 hours post-dose"
      },
      {
        "measure": "Volume of Distribution (V/F) of Selinexor in Plasma",
        "description": "Vz/F of selinexor in plasma was reported.",
        "timeFrame": "Cycle 1: Day 1: Pre-dose, 1, 2 and 4 hours post-dose; Day 8 and 15: Pre-dose and 1 hour post-dose; Cycle 2: Day 1: Predose, 1, 2 and 4 hours post-dose"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 20,
      "otherCount": 0,
      "totalCount": 21
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:47.645Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}